GS-5885, a NS5A inhibitor developed by Gilead for hepatitis C, has shown promising results in a recent study. Twenty five patients with genotype 1 chronic hepatitis C were given a combination of GS-5885, ribavirin, and sofosbuvir for 12 weeks.  Four weeks after finishing therapy, all patients showed an undetectable level of hepatitis C infection.  GS-5885 works by stopping the hepatitis C virus from replicating.  What medications are currently approved for hepatitis C infection?

For more information, please read the article from

“Image courtesy of [dream designs]/